MHRA will not limit the number of drugs that could be awarded the designation, but the lengthy, expensive application process could effectively limit the number of small firms that can take advantage of it.
Interest amongst drug manufacturers in the U.K. government’s Early Access to Medicines Scheme could see the potential number of qualifying drugs rise from a meager two per annum to four or even eight, according to presentations at a joint BioIndustry Association and Association of the British Pharmaceutical Industry event April 28.
Daniel O’Connor, Expert Medical Assessor at the U.K.’s Medicines and Healthcare Products Regulatory Agency said in his presentation on the...
Vincenza Trivigno will take over as executive director from Raimund Bruhin, who is retiring after over seven years in the post.
Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says the EU pharma reform is “not an improvement on the status quo” in its current form.
Oncology trial sponsors in the UK are being invited to participate in a pilot that aims to tackle duplication and variation in pharmacy reviews, which are an important part of setting up clinical trials in the National Health Service.
Expanded confidential pricing for pharmaceuticals is intended to help manage medicines expenditure, according to Amgros, the procurement agency that will negotiate the prices.
Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says the EU pharma reform is “not an improvement on the status quo” in its current form.
Oncology trial sponsors in the UK are being invited to participate in a pilot that aims to tackle duplication and variation in pharmacy reviews, which are an important part of setting up clinical trials in the National Health Service.
The new Advisory Committee on Immunization Practices voted for new recommendations on the decades-old thimerosal safety issue and lays intellectual groundwork to revisit other past controversies and decisions.
